Pembrolizumab Plus Chemotherapy Continues to Display Survival Advantage Over Chemotherapy in NSCLCMarch 24th 2023
Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.
Nonpharmacologic Pain Intervention Reduces Opioid Use Following Minimally Invasive Gynecologic and Urologic SurgeryMarch 23rd 2023
The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.
Patritumab Deruxtecan Makes Headway in Early Phase Trials for Patients With Metastatic EGFR+ NSCLC and HER3+ Breast CancerMarch 21st 2023
Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.
Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian CancerMarch 13th 2023
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.
Vaginal/Vulvar Symptoms Show Improvement With Lasofoxifene in Postmenopausal Women With ER+/HER2–, ESR1-Mutated Breast Cancer
Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.